Annexon (ANNX) Announces Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer

Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientifi

Dr. Ted Yednocks appointment enhances Annexons commitment to scientific innovation and pursuit of future programs

Dr. Larry Mattheakis brings decades of drug discovery and development expertise to support advancement of Annexons current and future pipeline

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Annexon) (Nasdaq: ANNX), a clinical-stage company developing a new class of medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Ted Yednock, Ph.D., as chief innovation officer (CIO), and the appointment... More